|
US7045313B1
(en)
|
1982-11-30 |
2006-05-16 |
The United States Of America As Represented By The Department Of Health And Human Services |
Recombinant vaccinia virus containing a chimeric gene having foreign DNA flanked by vaccinia regulatory DNA
|
|
US5168062A
(en)
|
1985-01-30 |
1992-12-01 |
University Of Iowa Research Foundation |
Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
|
|
IL85035A0
(en)
|
1987-01-08 |
1988-06-30 |
Int Genetic Eng |
Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
|
|
AU600575B2
(en)
|
1987-03-18 |
1990-08-16 |
Sb2, Inc. |
Altered antibodies
|
|
US5443964A
(en)
|
1987-08-10 |
1995-08-22 |
Duke University |
Poxvirus insertion/expression vector
|
|
US5716826A
(en)
|
1988-03-21 |
1998-02-10 |
Chiron Viagene, Inc. |
Recombinant retroviruses
|
|
US5208020A
(en)
|
1989-10-25 |
1993-05-04 |
Immunogen Inc. |
Cytotoxic agents comprising maytansinoids and their therapeutic use
|
|
US6410010B1
(en)
|
1992-10-13 |
2002-06-25 |
Board Of Regents, The University Of Texas System |
Recombinant P53 adenovirus compositions
|
|
JP3399943B2
(ja)
|
1991-05-06 |
2003-04-28 |
アメリカ合衆国 |
癌胎児性抗原を発現する組換えウイルスとその使用方法
|
|
CA2103059C
(en)
|
1991-06-14 |
2005-03-22 |
Paul J. Carter |
Method for making humanized antibodies
|
|
US5262522A
(en)
|
1991-11-22 |
1993-11-16 |
Immunex Corporation |
Receptor for oncostatin M and leukemia inhibitory factor
|
|
DE69329503T2
(de)
|
1992-11-13 |
2001-05-03 |
Idec Pharma Corp |
Therapeutische Verwendung von chimerischen und markierten Antikörpern, die gegen ein Differenzierung-Antigen gerichtet sind, dessen Expression auf menschliche B Lymphozyt beschränkt ist, für die Behandlung von B-Zell-Lymphoma
|
|
CA2163345A1
(en)
|
1993-06-16 |
1994-12-22 |
Susan Adrienne Morgan |
Antibodies
|
|
US5457035A
(en)
|
1993-07-23 |
1995-10-10 |
Immunex Corporation |
Cytokine which is a ligand for OX40
|
|
US20020159979A1
(en)
|
1994-06-06 |
2002-10-31 |
Children's Hospital, Inc. |
Adeno-associated virus materials and methods
|
|
DE69534702T2
(de)
|
1994-09-23 |
2006-08-24 |
The University Of British Columbia, Vancouver |
Verfahren zur erhöhung der expression von endogenen peptiden tragenden mhc klasse i molekulen
|
|
CA2201587C
(en)
|
1994-10-03 |
2002-06-25 |
Jeffrey Schlom |
Composition comprising a recombinant virus expressing an antigen and a recombinant virus expressing an immunostimulatory molecule
|
|
US5998205A
(en)
|
1994-11-28 |
1999-12-07 |
Genetic Therapy, Inc. |
Vectors for tissue-specific replication
|
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
|
US7153510B1
(en)
|
1995-05-04 |
2006-12-26 |
Yale University |
Recombinant vesiculoviruses and their uses
|
|
US5780426A
(en)
|
1995-06-07 |
1998-07-14 |
Ixsys, Incorporated |
Fivemer cyclic peptide inhibitors of diseases involving αv β3
|
|
US5767071A
(en)
|
1995-06-07 |
1998-06-16 |
Ixsys Incorporated |
Sevenmer cyclic peptide inhibitors of diseases involving αv β3
|
|
FR2735789B1
(fr)
|
1995-06-23 |
1997-07-25 |
Centre Nat Rech Scient |
Adenovirus recombinants, leur utilisation pour preparer des aav, lignee cellulaire complementaire et compositions pharmaceutiques les contenant
|
|
WO1997009441A2
(en)
|
1995-09-08 |
1997-03-13 |
Genzyme Corporation |
Improved aav vectors for gene therapy
|
|
US7001765B2
(en)
|
1996-03-06 |
2006-02-21 |
Medigene Ag |
Adeno-associated virus vector for boosting immunogenicity of cells
|
|
JP4213224B2
(ja)
|
1997-05-02 |
2009-01-21 |
ジェネンテック，インコーポレーテッド |
ヘテロマルチマー及び共通成分を有する多重特異性抗体の製造方法
|
|
EP1012236A1
(en)
|
1997-08-15 |
2000-06-28 |
Rubicon Laboratory Inc. |
Retrovirus and viral vectors
|
|
CA2304168A1
(en)
|
1997-09-19 |
1999-04-01 |
The Trustees Of The University Of Pennsylvania |
Methods and cell line useful for production of recombinant adeno-associated viruses
|
|
GB9801930D0
(en)
|
1998-01-29 |
1998-03-25 |
Univ London |
Mutant herpes simplex viruses and uses thereof
|
|
EP1068241B1
(en)
|
1998-04-02 |
2007-10-10 |
Genentech, Inc. |
Antibody variants and fragments thereof
|
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
|
US20040063094A1
(en)
|
1998-05-20 |
2004-04-01 |
Biovex Limited |
Mutant herpes simplex viruses and uses thereof
|
|
US6436392B1
(en)
|
1998-05-20 |
2002-08-20 |
University Of Iowa Research Foundation |
Adeno-associated virus vectors
|
|
GB2337755B
(en)
|
1998-05-29 |
2003-10-29 |
Secr Defence |
Virus vaccine
|
|
WO2000008051A2
(en)
|
1998-08-07 |
2000-02-17 |
University Of Washington |
Immunological herpes simplex virus antigens and methods for use thereof
|
|
WO2000028004A1
(en)
|
1998-11-10 |
2000-05-18 |
The University Of North Carolina At Chapel Hill |
Virus vectors and methods of making and administering the same
|
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
PL209786B1
(pl)
|
1999-01-15 |
2011-10-31 |
Genentech Inc |
Przeciwciało zawierające wariant regionu Fc ludzkiej IgG1, przeciwciało wiążące czynnik wzrostu śródbłonka naczyń oraz immunoadhezyna
|
|
GB9904582D0
(en)
|
1999-02-26 |
1999-04-21 |
Nycomed Imaging As |
Process
|
|
US6428968B1
(en)
|
1999-03-15 |
2002-08-06 |
The Trustees Of The University Of Pennsylvania |
Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject
|
|
DE19933288A1
(de)
|
1999-07-15 |
2001-01-18 |
Medigene Ag |
Strukturprotein von Adeno-assoziiertem Virus mit veränderter Antigenität, seine Herstellung und Verwendung
|
|
US6365619B1
(en)
|
1999-07-22 |
2002-04-02 |
Novartis Ag |
Treatment of arteriosclerosis
|
|
CA2379166C
(en)
|
1999-08-09 |
2013-03-26 |
Targeted Genetics Corporation |
Enhancement of expression of a single-stranded, heterologous nucleotide sequence from recombinant viral vectors by designing the sequence such that it forms instrastrand base pairs
|
|
US7241447B1
(en)
|
1999-10-07 |
2007-07-10 |
University Of Iowa Research Foundation |
Adeno-associated virus vectors and uses thereof
|
|
US7329728B1
(en)
|
1999-10-25 |
2008-02-12 |
The Scripps Research Institute |
Ligand activated transcriptional regulator proteins
|
|
US6723316B2
(en)
|
1999-12-22 |
2004-04-20 |
Onyx Pharmaceuticals, Inc. |
Herpes simplex virus-1 Glycoprotein C mutants for treating unwanted hyperproliferative cell growth
|
|
ES2254359T3
(es)
|
2000-01-21 |
2006-06-16 |
Biovex Limited |
Cepa viral para el tratamiento oncolitico de canceres.
|
|
US7306902B2
(en)
|
2002-06-28 |
2007-12-11 |
Oncolyties Biotech Inc. |
Oncolytic viruses as phenotyping agents for neoplasms
|
|
US7011972B2
(en)
|
2000-07-18 |
2006-03-14 |
The Scripps Research Institute |
Fusion polypeptide comprising two ligand binding domains
|
|
US6653103B2
(en)
|
2001-03-30 |
2003-11-25 |
Wisconsin Alumni Research Foundation |
Inhibition of nucleocytoplasmic transport by vesicular stomatitis virus M protein-like polypeptides
|
|
ATE500808T1
(de)
|
2001-05-11 |
2011-03-15 |
Wellstat Biologics Corp |
Onkolytische virustherapie
|
|
US20030044386A1
(en)
|
2001-07-11 |
2003-03-06 |
Barber Glen N. |
Recombinant VSV for the treatment of tumor cells
|
|
CN1304559C
(zh)
|
2001-10-09 |
2007-03-14 |
杭州康科生物技术有限公司 |
表达热休克蛋白的溶瘤微生物及其应用
|
|
EP1461073B1
(en)
|
2001-11-30 |
2010-01-06 |
The Government of the United States of America, as represented by the Secretary Department of Health and Human Services |
Peptide agonists of prostate-specific antigen, and uses therefor
|
|
US8188231B2
(en)
|
2002-09-27 |
2012-05-29 |
Xencor, Inc. |
Optimized FC variants
|
|
JP2005521398A
(ja)
|
2002-03-27 |
2005-07-21 |
ベイラー カレッジ オブ メディスン |
癌治療用の強力な腫瘍溶解性単純ヘルペスウイルス
|
|
US20030225260A1
(en)
|
2002-04-30 |
2003-12-04 |
Snyder Richard O. |
Production of recombinant AAV virions
|
|
CA2489523A1
(en)
|
2002-06-21 |
2003-12-31 |
Wellstat Biologics Corporation |
Administration of therapeutic viruses
|
|
EP1391213A1
(en)
|
2002-08-21 |
2004-02-25 |
Boehringer Ingelheim International GmbH |
Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents
|
|
JP2005537802A
(ja)
|
2002-09-09 |
2005-12-15 |
ユニバーシティ・オブ・テネシー・リサーチ・ファウンデーション |
ラブドウイルスの組み換え型変異体及びその使用方法
|
|
US7361740B2
(en)
|
2002-10-15 |
2008-04-22 |
Pdl Biopharma, Inc. |
Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
|
|
WO2004056312A2
(en)
|
2002-12-16 |
2004-07-08 |
Genentech, Inc. |
Immunoglobulin variants and uses thereof
|
|
EP2039773B1
(en)
|
2003-03-27 |
2011-12-28 |
Ottawa Hospital Research Institute |
Mutant vesicular stomatitis viruses and use thereof
|
|
US7731974B2
(en)
|
2003-03-27 |
2010-06-08 |
Ottawa Hospital Research Institute |
Mutant vesicular stomatitis viruses and uses thereof
|
|
ATE420160T1
(de)
|
2003-06-18 |
2009-01-15 |
Genelux Corp |
Modifizierte rekombinante vacciniaviren, verwendungen davon
|
|
CN102199626B
(zh)
|
2003-09-30 |
2015-06-24 |
宾夕法尼亚大学托管会 |
腺伴随病毒(aav)进化支、序列、含有这些序列的载体及它们的应用
|
|
US20070003520A1
(en)
|
2003-11-17 |
2007-01-04 |
Brown Susanne M |
Mutant viruses
|
|
US7897146B2
(en)
|
2003-11-17 |
2011-03-01 |
Crusade Laboratories Limited |
Treatment using herpes simplex virus
|
|
GB0326798D0
(en)
|
2003-11-17 |
2003-12-24 |
Crusade Lab Ltd |
Methods for generating mutant virus
|
|
AU2004309347B2
(en)
|
2003-12-19 |
2010-03-04 |
Genentech, Inc. |
Monovalent antibody fragments useful as therapeutics
|
|
JP4633788B2
(ja)
|
2004-04-13 |
2011-02-16 |
エフ．ホフマン−ラ ロシュ アーゲー |
抗ｐ−セレクチン抗体
|
|
WO2005116224A2
(en)
|
2004-05-18 |
2005-12-08 |
Children's Memorial Hospital |
Tetracycline-regulated adeno-associated viral (aav) vectors for gene delivery to the nervous system
|
|
US7427396B2
(en)
|
2004-06-03 |
2008-09-23 |
Genzyme Corporation |
AAV vectors for gene delivery to the lung
|
|
WO2006002394A2
(en)
|
2004-06-24 |
2006-01-05 |
New York University |
Avirulent oncolytic herpes simplex virus strains engineered to counter the innate host response
|
|
CA2565961A1
(en)
|
2004-07-15 |
2006-02-23 |
Xencor, Inc. |
Optimized fc variants
|
|
TWI380996B
(zh)
|
2004-09-17 |
2013-01-01 |
Hoffmann La Roche |
抗ｏｘ４０ｌ抗體
|
|
US8911726B2
(en)
|
2004-09-22 |
2014-12-16 |
Kyowa Hakko Kirin Co., Ltd |
Stabilized human Igg4 antibodies
|
|
US20100111856A1
(en)
|
2004-09-23 |
2010-05-06 |
Herman Gill |
Zirconium-radiolabeled, cysteine engineered antibody conjugates
|
|
US20090208924A1
(en)
|
2004-12-01 |
2009-08-20 |
Bayer Schering Pharma Aktiengesellschaft |
Generation of Replication Competent Viruses for Therapeutic Use
|
|
JP5620626B2
(ja)
|
2005-03-31 |
2014-11-05 |
中外製薬株式会社 |
会合制御によるポリペプチド製造方法
|
|
AU2006252406B2
(en)
|
2005-06-01 |
2012-05-17 |
California Institute Of Technology |
Method of targeted gene delivery using viral vectors
|
|
CN101495126B
(zh)
|
2005-06-23 |
2016-01-06 |
休斯顿大学 |
Ⅱ型单纯疱疹病毒突变体在治疗癌症中的用途
|
|
US7943374B2
(en)
|
2005-08-21 |
2011-05-17 |
Markus Hildinger |
Super-size adeno-associated viral vector harboring a recombinant genome larger than 5.7 kb
|
|
GB0522476D0
(en)
|
2005-11-03 |
2005-12-14 |
Biovex Ltd |
Oncolytic herpes virus vectors
|
|
PL2048955T3
(pl)
|
2006-07-21 |
2013-11-29 |
California Inst Of Techn |
Nakierowane dostarczanie genu dla szczepienia komórek dendrytycznych
|
|
US20090098529A1
(en)
|
2006-10-16 |
2009-04-16 |
Nanhai Chen |
Methods for attenuating virus strains for diagnostic and therapeutic uses
|
|
WO2008140621A2
(en)
|
2006-12-21 |
2008-11-20 |
Mount Sinai School Of Medicine Of New York University |
Transgenic oncolytic viruses and uses thereof
|
|
WO2008092117A2
(en)
|
2007-01-25 |
2008-07-31 |
Xencor, Inc. |
Immunoglobulins with modifications in the fcr binding region
|
|
GB2446721B
(en)
|
2007-02-16 |
2009-03-25 |
Crusade Lab Ltd |
Herpes simplex viruses and methods of viral replication
|
|
JP5213075B2
(ja)
|
2007-06-15 |
2013-06-19 |
ジェネラックス・コーポレイション |
腫瘍の画像化および／または処置のための微生物
|
|
EA021222B8
(ru)
|
2007-06-21 |
2015-11-30 |
ИксЭль-ПРОТЕИН ГМБХ |
Биологически активные белки, имеющие повышенную стабильность in vivo и/или in vitro
|
|
WO2009011924A1
(en)
|
2007-07-18 |
2009-01-22 |
Genelux Corporation |
Use of a chemotherapeutic agent in the preparation of a medicament for treating or ameliorating an adverse side effect associated with oncolytic viral therapy
|
|
EP2212696B1
(en)
|
2007-10-25 |
2013-12-04 |
Genelux Corporation |
Systems and methods for viral therapy
|
|
EP2225277A4
(en)
|
2007-11-27 |
2012-03-14 |
Viventia Biotech Inc |
ANTIBODIES TO A CANCER-ASSOCIATED EPITOPE OF THE VARIANT NFKBIB AND APPLICATIONS THEREOF
|
|
WO2009076524A2
(en)
|
2007-12-11 |
2009-06-18 |
The University Of North Carolina At Chapel Hill |
Polypurine tract modified retroviral vectors
|
|
US8313896B2
(en)
|
2008-04-04 |
2012-11-20 |
The General Hospital Corporation |
Oncolytic herpes simplex virus immunotherapy in the treatment of brain cancer
|
|
EP2300023A2
(en)
|
2008-05-16 |
2011-03-30 |
Genelux Corporation |
Microorganisms for preventing and treating neoplasms accompanying cellular therapy
|
|
WO2009148488A2
(en)
|
2008-05-29 |
2009-12-10 |
The General Hospital Corporation |
Use of oncolytic herpes viruses for killing cancer stem cells
|
|
EP3936122A1
(en)
|
2008-11-24 |
2022-01-12 |
Massachusetts Institute Of Technology |
Methods and compositions for localized agent delivery
|
|
WO2010080909A1
(en)
|
2009-01-08 |
2010-07-15 |
Yale University |
Compositions and methods of use of an oncolytic vesicular stomatitis virus
|
|
EP2283810A1
(en)
|
2009-07-16 |
2011-02-16 |
University College Cork-National University of Ireland, Cork |
Orally administered bacteria as vehicles for systemic delivery of agents
|
|
US20150359909A1
(en)
|
2009-07-16 |
2015-12-17 |
University College Cork-National University Of Ireland, Cork |
Orally administered bacteria as vehicles for systemic delivery of agents
|
|
SG177744A1
(en)
|
2009-07-24 |
2012-02-28 |
Immune Design Corp |
Lentiviral vectors pseudotyped with a sindbis virus envelope glycoprotein
|
|
RU2624027C2
(ru)
|
2010-04-23 |
2017-06-30 |
Дженентек, Инк. |
Получение гетеромультимерных белков
|
|
PH12013501201A1
(en)
|
2010-12-09 |
2013-07-29 |
Univ Pennsylvania |
Use of chimeric antigen receptor-modified t cells to treat cancer
|
|
US9402865B2
(en)
|
2011-01-18 |
2016-08-02 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for treating cancer
|
|
CA2830254C
(en)
|
2011-03-16 |
2019-09-10 |
Amgen Inc. |
Fc variants
|
|
WO2012141984A1
(en)
|
2011-04-08 |
2012-10-18 |
Immune Design Corp. |
Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
|
|
WO2012149364A1
(en)
|
2011-04-28 |
2012-11-01 |
Diamond Don J |
Tumor associated vaccines and compositions for disrupting tumor-derived immunosuppression for use in combination cancer immunotherapy
|
|
AU2012308205A1
(en)
|
2011-09-16 |
2014-03-13 |
The Trustees Of The University Of Pennsylvania |
RNA engineered T cells for the treatment of cancer
|
|
MX349096B
(es)
*
|
2011-11-28 |
2017-07-11 |
Merck Patent Gmbh |
Anticuerpos anti-pd-l1 y sus usos.
|
|
AU2013226090B2
(en)
|
2012-02-27 |
2018-03-08 |
Amunix Operating Inc. |
XTEN conjugate compositions and methods of making same
|
|
NZ700340A
(en)
|
2012-03-30 |
2017-02-24 |
Immune Design Corp |
Lentiviral vector particles having improved transduction efficiency for cells expressing dc- sign
|
|
US10117896B2
(en)
|
2012-10-05 |
2018-11-06 |
The Trustees Of The University Of Pennsylvania |
Use of a trans-signaling approach in chimeric antigen receptors
|
|
AR093984A1
(es)
*
|
2012-12-21 |
2015-07-01 |
Merck Sharp & Dohme |
Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
|
|
US9562099B2
(en)
|
2013-03-14 |
2017-02-07 |
Genentech, Inc. |
Anti-B7-H4 antibodies and immunoconjugates
|
|
CA2903546A1
(en)
|
2013-03-15 |
2014-09-25 |
Biogen Ma Inc. |
Treatment and prevention of acute kidney injury using anti-alpha v beta 5 antibodies
|
|
WO2014198002A1
(en)
|
2013-06-14 |
2014-12-18 |
Ottawa Hospital Research Institute |
A bacterium producing an interferon binding protein and uses thereof
|
|
WO2015103438A2
(en)
|
2014-01-02 |
2015-07-09 |
Genelux Corporation |
Oncolytic virus adjunct therapy with agents that increase virus infectivity
|
|
RU2727639C2
(ru)
|
2014-01-15 |
2020-07-22 |
Ф.Хоффманн-Ля Рош Аг |
Варианты fc-области с модифицированной способностью связываться с fcrn и с сохраненной способностью связываться с белком а
|
|
WO2016011083A1
(en)
|
2014-07-15 |
2016-01-21 |
Immune Design Corp. |
Prime-boost regimens with a tlr4 agonist adjuvant and a lentiviral vector
|
|
EP3020816A1
(en)
|
2014-11-11 |
2016-05-18 |
University College Cork |
Bacterial mediated gene therapy
|
|
EP3283508B1
(en)
*
|
2015-04-17 |
2021-03-17 |
Alpine Immune Sciences, Inc. |
Immunomodulatory proteins with tunable affinities
|
|
CN114767833A
(zh)
*
|
2015-08-20 |
2022-07-22 |
弗劳恩霍夫应用研究促进协会 |
B7-h1融合多肽或多核苷酸用于治疗或预防肝衰竭的用途
|
|
EP3491013A1
(en)
*
|
2016-07-28 |
2019-06-05 |
Alpine Immune Sciences, Inc. |
Cd155 variant immunomodulatory proteins and uses thereof
|
|
WO2018022945A1
(en)
*
|
2016-07-28 |
2018-02-01 |
Alpine Immune Sciences, Inc. |
Cd112 variant immunomodulatory proteins and uses thereof
|
|
US20230220039A1
(en)
*
|
2017-03-16 |
2023-07-13 |
Alpine Immune Sciences, Inc. |
Pd-l1 variant immunomodulatory proteins and uses thereof
|